BDI licenses novel separation technology to two Swedish diagnostic companies

BDI (The Biomedical Diagnostic Institute) has recently licensed its novel separation technology to two Swedish diagnostic companies, Fiomi Diagnostics A.B and Calmark Sweden A.B. Fiomi Diagnostic’s vision is to bring game-changing products to the professional Point of Care market by exploiting microfluidic technology for open lateral flow immunoassays. Calmark Sweden AB is focused on the development of biomarker solutions for point-of-care detection of critical illness. The “Lab in a Trench” technology developed at the BDI by Prof. Jens Ducrée’s group provides a revolutionary approach to the separation of red blood cells from plasma. This BDI technology will be combined with Fiomi and Calmark’s platforms for high-performance whole blood immunoassays at the point of care. For more information, please contact emma.oneill@invent.dcu.ie